Search
SKI researchers have learned how tiny droplets prevent a cancer-causing type of messenger RNA from being degraded in leukemia cells.
Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.
Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.
Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009.
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.
Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.
Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.
Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty.
The tool will aid basic and translational researchers interested in understanding why immune cells stop working.